Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare...(ss and automated external defibrillation...),Health

Date:10/20/2009

ss, and automated external defibrillation sales into the physician office. In addition, they have a strong direct sales force in the hospital market. They've demonstrated their commitment and skill selling into both marketplaces - which is exactly what we needed."

Vital signs monitors sold under the exclusive agreement are available for sale next Monday under the Cardiac Science name, while clearly featuring the accuracy of the OMRON technology. "This allows customers to recognize the strengths of both brands, and know they're purchasing from a partnership comprising two world leaders," Kondraske added.

About Cardiac Science

Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, Holter monitoring systems, hospital defibrillators, '/>"/>

SOURCE Cardiac Science Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Cellular Dynamics International and VivoMedica Launch the CARDIOTOX Consortium to Validate a Human Cardiac Model for Preclinical Cardiotoxicity Testing
2. Video: MADIT-CRT Trial Results Provide Clinical Evidence That Cardiac Resynchronization Therapy Significantly Slows Heart Failure Progression
3. Treatment Shows Excellent Results for Providence Tarzana Patients Following Cardiac Arrest
4. Worlds First Cardiac Adult Stem Cell Patient Receives Infusion
5. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
6. Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
7. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
8. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
9. Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
10. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
11. Cardiac Disease in Women Remains Untreated for Decades